Earnings call · Apr–Jun 2026
Advanced Enzyme Technologies Limited
Advanced Enzyme reported Apr–Jun 2026 revenue of ₹190 crore, up 2% from a year earlier but down 7% from the previous quarter, with EBITDA margin declining to 27% from 30% due to higher energy costs & a ₹10 crore revenue reversal. Management expects double-digit growth for the full year & 30% EBITDA margin recovery.
The full notes: numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Ronak SarafInvestor Relations Manager
- Mukund KabraWhole Time Director
Questions came from
- Lakshmi NarayananTunga Investments
- Abhishek NavalgundNirmal Bang Securities
- Zaki NasserNasser
- Umang ShahBanyan Tree Advisors
- Ravi PurohitSecurities Investment Management
- Shreyans GathaniSG Securities
- Abhishek KamdarValue Plus Advisors LLP
- SuryanshAIONOS
- Ketan Chheda
- Rohit OhriProgressive Shares
- Nikhil UpadhyaySecurities Investment Management
Topics in this call
Opening remarks
Mukund KabraWhole Time Director
Thank you, Ronak. Good evening, everyone. Thank you for joining us today for our Q1 FY27 Earnings Call. I extend a warm welcome to all our shareholders and partners. The global economy has been experiencing significant disturbance for quite some time, primarily driven by geographical tensions, trade and uncertainties, and continued disruption across global supply chain. These challenges have had a direct impact on the pricing of energy and certain raw materials, creating a volatile operating environment for businesses globally.
Against this backdrop, our Q1 performance reflects a softer, more muted start to the fiscal year. However, the fundamental strength of our business remains firmly intact, and we anticipate progressive momentum as the year advances. While it is important to view this performance in the context of the inherent nature of our business, that's the reason we always suggest all our shareholders to evaluate our business on an annual horizon rather than through the length of a single quarter.
Read the whole call: 247 paragraphs, 14 analysts' questions with every answer, 7 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript the company filed on BSE as scanned pages, read into text by AI (Claude): a word may be misread, so check the original PDF for anything important. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.